Report : Asia Pacific Transdermal Drug Delivery System Market Forecast to 2030 - Regional Analysis - by Type (Transdermal Patches, Transdermal Gel, Transdermal Sprays, and Others), Application (Cardiovascular Diseases, Central Nervous System Disorders, Pain Management, Hormonal Applications, and Other Applications), and Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
At 4.5% CAGR, Asia Pacific Transdermal Drug Delivery System Market is Speculated to be Worth US$ 12,820.77 million by 2030, says Business Market Insights
According to Business Market Insights' research, the Asia Pacific transdermal drug delivery system market was valued at US$ 9,029.89 million in 2022 and is expected to reach US$ 12,820.77 million by 2030, registering a CAGR of 4.5% from 2022 to 2030. Increasing prevalence of chronic diseases and growing demand for noninvasive drug delivery devices are among the critical factors attributed to the Asia Pacific transdermal drug delivery system market expansion.
Traditional drug delivery techniques such as intramuscular, intravenous, and rectal drug administration are not preferred by certain patient populations mainly due to the pain and complexities associated with them. With the improvements in medical science and definite drug delivery technologies, noninvasive drug delivery systems are now set to compete with the traditional method of injectable route of drug administration. The noninvasive drug delivery systems include drug delivery via oral; topical; transdermal-active (device-aided enhanced penetration) and transdermal-passive; and transocular membrane, transmucosal membrane, and alveolar membrane from inhaled medication. Transdermal drug delivery is advantageous in many ways over the oral route of administration. In particular, it evades the first-pass mechanism of the liver, which can otherwise impulsively metabolize drugs.
Further, transdermal delivery is not as painful as hypodermic injections, and this route leads to no dangerous medical waste and poses no risk of disease transmission by needle reuse, which is especially common in developing and under-developed countries. In addition, a noninvasive transdermal drug delivery system has simplified dosing schedules, and the drugs can be self-administered. Patient compliance is much higher when drugs are administrated noninvasively due to low or no pain involved. Therefore, this route is considered a preferred mode of drug delivery. Moreover, a non-invasive drug delivery system can significantly reduce the cost of clinical use because of the self-administration of the drugs by the patients. Thus, the advantages associated with a noninvasive drug delivery facilitated by transdermal drug delivery systems drive the market growth.
On the contrary, adverse effects and recall of transdermal drug delivery systems hamper the Asia growth of Pacific transdermal drug delivery system market.
Based on type, the Asia Pacific transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held 39.9% share of Asia Pacific transdermal drug delivery system market in 2022, amassing US$ 3,602.70 million. It is projected to garner US$ 5,216.66 million by 2030 to expand at 4.7% CAGR during 2022-2030. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.
In terms of application, the Asia Pacific transdermal drug delivery system market is categorized into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held 40.8% share of Asia Pacific transdermal drug delivery system market in 2022, amassing US$ 3,683.57 million. It is projected to garner US$ 5,226.18 million by 2030 to expand at 4.5% CAGR during 2022-2030. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.
By distribution channel, the Asia Pacific transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held 43.1% share of Asia Pacific transdermal drug delivery system market in 2022, amassing US$ 3,892.91 million. It is projected to garner US$ 5,522.33 million by 2030 to expand at 4.5% CAGR during 2022-2030.
Based on country, the Asia Pacific transdermal drug delivery system market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 31.6% share of Asia Pacific transdermal drug delivery system market in 2022. It was assessed at US$ 2,850.18 million in 2022 and is likely to hit US$ 4,156.97 million by 2030, exhibiting a CAGR of 4.8% during 2022-2030.
Key players operating in the Asia Pacific transdermal drug delivery system market are Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Luye Pharma Group Ltd, Novartis AG, and Viatris Inc, among others.
- In October 2023, Novartis completed the Spin-off of Sandoz, its Generics and Biosimilars business. Novartis executed separation of the Sandoz business to create an independent company by way of a 100% Spin-off.
- In December 2022, Luye Pharma Group held an offline product has launched conference in Shanghai, together with an online event, to announce the launch of Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets) in China. Ruoxinlin is China's first class 1 innovative chemical drug independently developed locally for the treatment of Major Depressive Disorder (MDD) and protected by intellectual property rights. The drug provides a powerful new option for patients, bringing the treatment of MDD to a new level.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com